Stay updated with breaking news from Biofoundry Services. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Codex DNA (NASDAQ:DNAY – Get Rating) and Cue Health (NASDAQ:HLTH – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends. Insider and Institutional Ownership 87.6% of Codex DNA shares […]
Codex DNA (NASDAQ:DNAY – Get Rating) is one of 42 publicly-traded companies in the “Analytical instruments” industry, but how does it weigh in compared to its competitors? We will compare Codex DNA to similar businesses based on the strength of its profitability, analyst recommendations, valuation, risk, institutional ownership, dividends and earnings. Profitability This table compares […]
Codex DNA, Inc. (NASDAQ:DNAY – Get Rating) – Jefferies Financial Group upped their FY2022 earnings estimates for Codex DNA in a note issued to investors on Wednesday, May 11th. Jefferies Financial Group analyst B. Couillard now anticipates that the company will post earnings of ($2.10) per share for the year, up from their prior forecast […]
Codex DNA (NASDAQ:DNAY – Get Rating) issued its quarterly earnings data on Wednesday. The company reported ($0.45) EPS for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.05, MarketWatch Earnings reports. Codex DNA had a negative return on equity of 43.84% and a negative net margin of 311.52%. Shares of NASDAQ:DNAY traded up $0.11 […]
Codex DNA (NASDAQ:DNAY – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Friday, Zacks.com reports. According to Zacks, “Codex DNA Inc. is a creator of the BioXp(TM) system, a fully automated benchtop instrument which enables numerous synthetic biology workflows. […]